EMISMEDIUM SIGNALFINANCIAL10-Q

EMIS transitioned from having no cash at June 30, 2025 to holding $1.4 million in cash at September 30, 2025, while maintaining $115 million in its trust account as this blank check company progresses through its early operational phase.

The company's improved liquidity position and positive working capital of $1.3 million represents a meaningful development for this recently incorporated SPAC. Management's assessment that no additional fundraising is needed for current operations suggests the company is adequately capitalized for its near-term business combination search activities.

Comparing 2025-11-13 vs 2025-11-04View on EDGAR →
FINANCIAL ANALYSIS

The company's financial position improved notably during the quarter, with cash holdings rising to $1.4 million from zero in the prior period, transforming a working capital deficit into a surplus. Operating losses increased meaningfully as expected for a newly formed blank check company beginning its operations. The trust account remains substantial at $115 million, providing the foundation for future acquisition activities while current liabilities grew modestly to $125,000.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-74.2%
-$95K-$165K

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Liabilities
Balance Sheet
+29.2%
$97K$125K

Liabilities increased 29.2% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+29.2%
$97K$125K

Current liabilities rose 29.2% — increased short-term obligations, watch current ratio.

Stockholders Equity
Balance Sheet
-15.4%
$1.1M$909K

Equity decreased 15.4% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2025-11-13
PRIOR — 2025-11-04
ADDED
(the Company ) is a blank check company incorporated as a Cayman Islands exempted company on March 21, 2025.
As of September 30, 2025, the Company had not commenced any operations.
At September 30, 2025, the Company had $ 1,446,437 cash and had a working capital surplus of $ 1,265,828 .
In connection with the Company s assessment of going concern considerations in accordance with Accounting Standards Codification ( ASC ) 205-40, Presentation of Financial Statements - Going Concern , the Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating its business.
The Company had $ 1,446,437 in cash and no cash equivalents as of September 30, 2025.
+7 more — sign up free →
REMOVED
1 0002075816 --12-31 false Q2 Rights, each right entitling the holder to receive one-tenth (1/10) of one http://fasb.org/srt/2025#ChiefFinancialOfficerMember (1) Excludes an aggregate of 500,000 Class B ordinary shares subject to forfeiture if the over-allotment is not exercised in full or in part by the underwriters.
Includes an aggregate of 500,000 Class B ordinary shares subject to forfeiture if the over-allotment is not exercised in full or in part by the underwriters.
Interim Financial Statements Condensed Balance Sheet as of June 30, 2025 (Unaudited) 1 Condensed Statements of Operations for the three months ended and for the period from March 21, 2025 (Inception) through June 30, 2025 (Unaudited) 2 Condensed Statements of Changes in Shareholder s Deficit for the three months ended and for the period from March 21, 2025 (Inception) through June 30, 2025 (Unaudited) 3 Condensed Statement of Cash Flows for the period from March 21, 2025 (Inception) through June 30, 2025 (Unaudited) 4 Notes to Condensed Financial Statements (Unaudited) 5 Item 2.
(the Company ) is a blank check company incorporated as a Cayman Islands exempted company on March 21, 2025 .
As of June 30, 2025, the Company had not commenced any operations.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →